Hemogenyx Pharmaceuticals Plc Stock Shares Outstanding
HOPHF Stock | USD 0 0.00 0.00% |
Hemogenyx Pharmaceuticals Plc fundamentals help investors to digest information that contributes to Hemogenyx Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Hemogenyx Pink Sheet. The fundamental analysis module provides a way to measure Hemogenyx Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hemogenyx Pharmaceuticals pink sheet.
Hemogenyx |
Hemogenyx Pharmaceuticals Plc Company Shares Outstanding Analysis
Hemogenyx Pharmaceuticals' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Hemogenyx Pharmaceuticals Shares Outstanding | 1.14 B |
Most of Hemogenyx Pharmaceuticals' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemogenyx Pharmaceuticals Plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Competition |
Based on the latest financial disclosure, Hemogenyx Pharmaceuticals Plc has 1.14 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is 99.71% lower than that of the firm.
Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
All Next | Launch Module |
Hemogenyx Fundamentals
Return On Equity | -0.32 | |||
Return On Asset | -0.18 | |||
Current Valuation | 8.17 M | |||
Shares Outstanding | 1.14 B | |||
Shares Owned By Insiders | 13.01 % | |||
Price To Book | 1.78 X | |||
EBITDA | (2.39 M) | |||
Net Income | (5.1 M) | |||
Cash And Equivalents | 6.84 M | |||
Cash Per Share | 0.01 X | |||
Total Debt | 10.15 K | |||
Debt To Equity | 0 % | |||
Current Ratio | 20.23 X | |||
Book Value Per Share | 0.01 X | |||
Cash Flow From Operations | (2.63 M) | |||
Earnings Per Share | (0.01) X | |||
Number Of Employees | 10 | |||
Beta | 3.49 | |||
Market Capitalization | 45.68 M | |||
Total Asset | 8.52 M | |||
Net Asset | 8.52 M |
About Hemogenyx Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemogenyx Pharmaceuticals Plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemogenyx Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemogenyx Pharmaceuticals Plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Hemogenyx Pink Sheet
Hemogenyx Pharmaceuticals financial ratios help investors to determine whether Hemogenyx Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Hemogenyx with respect to the benefits of owning Hemogenyx Pharmaceuticals security.